Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hemispherx Biopharma has received Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) approval for the sale and distribution of Alferon N Injection (Naturaferon) in Argentina.
Subscribe to our email newsletter
Alferon N Injection (Interferon alfa-n3 (human leukocyte derived)) is even approved in the US for the treatment of refractory or recurring external condylomata acuminate (genital warts) in adults.
The company is manufacturing Alferon N Injection at its New Brunswick, New Jersey facility.
Hemispherx executive vice chairman Thomas Equels said the approval is the result of its global business development initiatives which it plans to continue and to expand.
"We are confident about the commercial opportunities for Alferon N Injection in Argentina and pleased with the progress GP Pharm has made as is evidenced by this approval," Equels added.